Reaction Details Report a problem with these data
Target
Cathepsin D
Ligand
BDBM50061598
Substrate
n/a
Meas. Tech.
ChEMBL_1461647 (CHEMBL3395116)
IC50
1040±n/a nM
Citation
Chen, JJ; Liu, Q; Yuan, C; Gore, V; Lopez, P; Ma, V; Amegadzie, A; Qian, W; Judd, TC; Minatti, AE; Brown, J; Cheng, Y; Xue, M; Zhong, W; Dineen, TA; Epstein, O; Human, J; Kreiman, C; Marx, I; Weiss, MM; Hitchcock, SA; Powers, TS; Chen, K; Wen, PH; Whittington, DA; Cheng, AC; Bartberger, MD; Hickman, D; Werner, JA; Vargas, HM; Everds, NE; Vonderfecht, SL; Dunn, RT; Wood, S; Fremeau, RT; White, RD; Patel, VF Development of 2-aminooxazoline 3-azaxanthenes as orally efficaciousß-secretase inhibitors for the potential treatment of Alzheimer's disease. Bioorg Med Chem Lett 25:767-74 (2015) [PubMed] Article
More Info.:
Target
Name:
Cathepsin D
Synonyms:
CATD_HUMAN | CPSD | CTSD | Cathepsin D [Precursor] | Cathepsin D heavy chain | Cathepsin D light chain | Cathepsin D precursor
Type:
Enzyme
Mol. Mass.:
44551.72
Organism:
Human
Description:
Human proCathepsin D (SwissProt accession number P07339) was expressed in Sf9 cells, purified, and autoactivated.
Residue:
412
Sequence:
MQPSSLLPLALCLLAAPASALVRIPLHKFTSIRRTMSEVGGSVEDLIAKGPVSKYSQAVPAVTEGPIPEVLKNYMDAQYYGEIGIGTPPQCFTVVFDTGSSNLWVPSIHCKLLDIACWIHHKYNSDKSSTYVKNGTSFDIHYGSGSLSGYLSQDTVSVPCQSASSASALGGVKVERQVFGEATKQPGITFIAAKFDGILGMAYPRISVNNVLPVFDNLMQQKLVDQNIFSFYLSRDPDAQPGGELMLGGTDSKYYKGSLSYLNVTRKAYWQVHLDQVEVASGLTLCKEGCEAIVDTGTSLMVGPVDEVRELQKAIGAVPLIQGEYMIPCEKVSTLPAITLKLGGKGYKLSPEDYTLKVSQAGKTLCLSGFMGMDIPPPSGPLWILGDVFIGRYYTVFDRDNNRVGFAEAARL